Intensity Therapeutics, Inc. SEC filings INTS
Intensity Therapeutics, Inc. has 246 filings in SEC EDGAR's recent list, going back to Jan 18, 2013. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 16, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2026 | Mar 27, 2026 |
| 8-K |
Current report
Other events
|
Mar 23, 2026 | Mar 23, 2026 |
| 8-K |
Current report
Other events
|
Mar 6, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2026 | Mar 5, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Feb 13, 2026 | Feb 13, 2026 |
| 8-K |
Current report
Listing notice
|
Dec 5, 2025 | Dec 4, 2025 |
| 8-K |
Current report
Other events
|
Dec 4, 2025 | Dec 4, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 31, 2025 | Oct 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Oct 23, 2025 | Oct 22, 2025 |
| 8-K |
Current report
Other events
|
Sep 10, 2025 | Sep 10, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Aug 12, 2025 | Aug 8, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2025 | Aug 7, 2025 |
| 8-K |
Current report
Other events
|
Aug 4, 2025 | Aug 4, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 18, 2025 | Jul 17, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Other events
|
Jun 13, 2025 | Jun 11, 2025 |
| 8-K |
Current report
Listing notice
|
Jun 6, 2025 | Jun 6, 2025 |
| 8-K |
Current report
Listing notice
|
May 20, 2025 | May 19, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Apr 25, 2025 | Apr 24, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Apr 23, 2025 | Apr 22, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 13, 2025 | Mar 13, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Nov 22, 2024 | Nov 21, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Officer or director change
|
Oct 23, 2024 | Oct 21, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jul 17, 2024 | Jul 17, 2024 |
| 8-K |
Current report
Material agreement
|
Jul 3, 2024 | Jul 3, 2024 |
| 8-K |
Current report
Officer or director change
|
May 24, 2024 | May 21, 2024 |
| 8-K |
Current report
Officer or director change
|
May 15, 2024 | May 14, 2024 |
| 8-K |
Current report
Material agreement
|
May 10, 2024 | May 6, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| 8-K |
Current report
Listing notice
|
Apr 19, 2024 | Apr 18, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 14, 2024 | Mar 14, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 7, 2024 | Feb 6, 2024 |
| 8-K |
Current report
Officer or director change
|
Dec 12, 2023 | Dec 11, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Nov 22, 2023 | Nov 21, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2023 | Nov 13, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 5, 2023 | Sep 5, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2023 | Aug 14, 2023 |
| 8-K |
Current report
Other events
|
Jul 10, 2023 | Jul 10, 2023 |
| 8-K |
Current report
Material agreement, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 5, 2023 | Jun 29, 2023 |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- INTS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Shelton, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1567264
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.